News & Updates

Nonrheumatic SPAM not uncommon in young men

Nonrheumatic streptococcal pharyngitis-associated myocarditis (SPAM) appears to occur more frequently than previously believed, particularly in young men presenting with sore throat and fever, suggests a recent study.

Nonrheumatic SPAM not uncommon in young men

15 hours ago

Novel agent lowers LDL-C in ASCVD at-risk patients

16 May 2025

Inhibition of angiopoietin-like 3 (ANGPTL-3) with SHR-1918 leads to further low-density lipoprotein cholesterol (LDL-C) reductions in patients at increased risk of atherosclerotic cardiovascular disease (ASCVD), a phase II study has shown.

Novel agent lowers LDL-C in ASCVD at-risk patients

16 May 2025

Starting DOACs sooner after stroke may be best for AF patients

15 May 2025 by

For secondary stroke prevention in patients with atrial fibrillation (AF), the optimal timing of initiating a direct oral anticoagulant (DOAC) remains elusive, although evidence from a phase II study suggests that earlier initiation is better than later times within the first 2 weeks after stroke onset.

Starting DOACs sooner after stroke may be best for AF patients

15 May 2025

Tirzepatide eases MetS, cardiometabolic abnormalities in T2D

15 May 2025

Individuals with type 2 diabetes (T2D) may benefit from using tirzepatide, which has been shown in a recent study to improve cardiometabolic abnormalities and resolve metabolic syndrome (MetS).

Tirzepatide eases MetS, cardiometabolic abnormalities in T2D

15 May 2025

Rivaroxaban a game-changer for acute LV thrombus post-MI

15 May 2025 by

Patients who develop an acute thrombus in the left ventricle (LV) following myocardial infarction (MI) fare equally well when treated with rivaroxaban as they do with warfarin, as shown in the RIVAWAR study.

Rivaroxaban a game-changer for acute LV thrombus post-MI

15 May 2025

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

14 May 2025

The safety of nivolumab anticancer therapy may be improved through close collaboration between cardiology and oncology specialists, which can help detect cardiac complications early and manage these conditions effectively, suggests a study.

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

14 May 2025

Age not a factor in safety, effectiveness of pulse‐field ablation for AF

14 May 2025

Pulsed-field ablation for atrial fibrillation (AF) appears to be equally safe and effective in older patients as it is in their younger counterparts, according to a study.

Age not a factor in safety, effectiveness of pulse‐field ablation for AF

14 May 2025

Fluid restriction good for chronic HF: Aye or nay?

14 May 2025 by

Allowing patients with chronic heart failure (HF) to drink as much fluid as they need appears to present no additional risks, including for hospitalization and death, as shown in the FRESH-UP study presented at ACC.25. This finding challenges the current US and EU recommendations to limit daily fluid intake to 1.5 L for this population.

Fluid restriction good for chronic HF: Aye or nay?

14 May 2025

Intensive BP-lowering therapy safe for patients with acute ICH

13 May 2025

Reducing systolic blood pressure (SBP) to a target of less than 140 mm Hg does not appear to have any negative effects on diffusion-weighted imaging lesion frequency and volume in patients with acute intracerebral haemorrhage (ICH), as shown in ICHADAPT-2*.

Intensive BP-lowering therapy safe for patients with acute ICH

13 May 2025

Long-term use of antidepressants linked to sudden cardiac death

13 May 2025 by

New research presented at EHRA 2025 has shown that patients who have taken antidepressants for extended periods are at increased risk of sudden cardiac death.

Long-term use of antidepressants linked to sudden cardiac death

13 May 2025

News & Updates

Filter by Specialty:

Specialty:

Nonrheumatic SPAM not uncommon in young men

Nonrheumatic SPAM not uncommon in young men

Novel agent lowers LDL-C in ASCVD at-risk patients

Novel agent lowers LDL-C in ASCVD at-risk patients

Starting DOACs sooner after stroke may be best for AF patients

Starting DOACs sooner after stroke may be best for AF patients

Tirzepatide eases MetS, cardiometabolic abnormalities in T2D

Tirzepatide eases MetS, cardiometabolic abnormalities in T2D

Rivaroxaban a game-changer for acute LV thrombus post-MI

Rivaroxaban a game-changer for acute LV thrombus post-MI

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

Cardio-onco collab may enhance safety of nivolumab anticancer therapy

Age not a factor in safety, effectiveness of pulse‐field ablation for AF

Age not a factor in safety, effectiveness of pulse‐field ablation for AF

Fluid restriction good for chronic HF: Aye or nay?

Fluid restriction good for chronic HF: Aye or nay?

Intensive BP-lowering therapy safe for patients with acute ICH

Intensive BP-lowering therapy safe for patients with acute ICH

Long-term use of antidepressants linked to sudden cardiac death

Long-term use of antidepressants linked to sudden cardiac death